Savient Pharmaceuticals, Inc. and Teva Pharmaceuticals Industries Ltd. have launched Tev-Tropin (somatropin (rDNA origin) for injection), a growth hormone product for the treatment of children with short stature due to growth hormone deficiency, in US. This product was clinically tested and FDA-approved for growth hormone deficiency (GHD), and is manufactured by Savient using recombinant DNA (rDNA) technology.
Teva has begun offering Tev-Tropin to paediatric endocrinologists through its fully owned GATE Pharmaceuticals sales force. To maximize value to physicians and patients and to support optimal outcomes, Teva is providing a comprehensive patient support programme known as Growth Solutions, including a patient enrolment programme and call centre located within Teva Neuroscience, Inc. Growth Solutions(SM) utilizes world-class customer relationship management technology that is also currently being used to support Copaxone, Teva's successful multiple sclerosis drug, and its respective Shared Solutions patient support programme.
"We welcome any new drug that makes treatment for growth hormone deficiency more accessible for patients and their families," Patricia Costa, executive director of the Human Growth Foundation, said adding, "Tev-Tropin in concert with the Growth Solutions(SM) support programme bring more choice and clarity to these families."